Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
Volume: 22, Issue: 6, Pages: e237 - e237
Published: Jun 1, 2021
Abstract
In their study in The Lancet Oncology, Joaquim Bellmunt and colleagues 1 Bellmunt J Hussain M Gschwend JE et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22: 525-537 Summary Full Text Full Text PDF PubMed Scopus (14) Google Scholar have investigated the role of adjuvant checkpoint inhibitors in patients with high-risk...
Paper Details
Title
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
Published Date
Jun 1, 2021
Volume
22
Issue
6
Pages
e237 - e237
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History